Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04922944 · ClinicalTrials.gov registry record
Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients
A clinical trial of COVID-19 and Vaccine Reaction, sponsored by Huntington Memorial Hospital.
- Completed
- Registry status
- 167
- Enrollment target
- 1
- Study location
NCT04922944: Completed study of COVID-19 and Vaccine Reaction, sponsored by Huntington Memorial Hospital.
NCT04922944 is a study of COVID-19 and Vaccine Reaction that has completed, run by Huntington Memorial Hospital. The registered enrollment target is 167 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04922944, a study of COVID-19 and Vaccine Reaction, has completed, sponsored by Huntington Memorial Hospital.
- COMPLETED
- Registry status
- 167 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying how healthcare worker recipients react after receiving vaccinations for COVID-19. The objective of the study is to evaluate the immune response to COVID-19 vaccination. The immunity will be evaluated over time by measuring serum semi-quantitative SARS-Co-V2 IgG from blood specimens and analyzing vaccine reaction data. SARS-CoV-2 is the name for the virus responsible for COVID-19 infections. IgG, immunoglobulin G, is an antibody found in the blood that protects against bacterial and viral infections. Study subjects will also be asked to report physical reactions they may have experienced related to vaccinations.
Primary Outcome
Semi-quantitative SARS-CoV-2 IgG titer
Conditions Studied
Interventions
- DRUG COVID-19 vaccine
Study Locations (1)
California
- Huntington Hospital - Pasadena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2021-03-08 |
| Est. Completion | 2022-03-01 |
What the finished NCT04922944 record still lists
NCT04922944 is an observational study that tracks outcomes without assigning an intervention. The registered 167 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which COVID-19 vaccine is the first listed.
NCT04922944 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04922944 about?
NCT04922944 is a clinical study titled "Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients". This research study is studying how healthcare worker recipients react after receiving vaccinations for COVID-19. The objective of the study is to evaluate the immune response to COVID-19 vaccination. The immunity will be evaluated over time by measuring serum semi-quantitative SARS-Co-V2 IgG from b...
What is the current status of trial NCT04922944?
This trial is currently completed. The enrollment target is 167 participants. The study started on 2021-03-08. Estimated completion is 2022-03-01.
What conditions does trial NCT04922944 study?
This clinical trial studies the following conditions: COVID-19, Vaccine Reaction.
What interventions are being tested in trial NCT04922944?
The interventions under investigation include: COVID-19 vaccine (DRUG).
Who is sponsoring clinical trial NCT04922944?
This trial is sponsored by Huntington Memorial Hospital, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04922944 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04922944's enrollment target sits among peer trials
167 166th of 298 higher than 133 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04248283 · 167 participants · NA
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
- NCT04552509 · 167 participants · NA
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
- NCT05516277 · 167 participants · NA
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI